CXCR3 and amyotrophic lateral sclerosis: Similarly, the ALS patients shared higher CXCR3+EOMES+ subset proportions in the validation cohort (4.8 [IQR: 3.2–7.3] vs. 2.4 [IQR: 1.6–3.6], p < 0.001, Figure 1G).